Screener
Zevra Therapeutics, Inc. ZVRA Business Segments — Net income (loss)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001434647-26-000068
| Line item | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Total other (expense) income | (3,983) | 147,945 | (11,324) | 151,390 |
| Income before income taxes | 12,794 | 76,906 | 57,599 | 74,989 |
| Income tax expense | (4,042) | (2,199) | (10,957) | (3,381) |
| Net income | $8,752 | $74,707 | $46,642 | $71,608 |
| Net income per share of common stock: | ||||
| Basic | $0.14 | $1.24 | $0.76 | $1.20 |
| Diluted | $0.14 | $1.21 | $0.74 | $1.16 |
| Weighted-average shares of common stock outstanding: |
ITEM 1.FINANCIAL STATEMENTS
FAQ
- What is Zevra Therapeutics, Inc.'s business segments — net income (loss)?
- Zevra Therapeutics, Inc. (ZVRA) reported business segments — net income (loss) of $8.75M in Q2 2026.
- How has Zevra Therapeutics, Inc.'s business segments — net income (loss) changed year-over-year?
- Zevra Therapeutics, Inc.'s business segments — net income (loss) decreased by 88.3% year-over-year, from $74.71M to $8.75M.
- What does business segments — net income (loss) mean?
- Represents the final bottom-line profitability of the business segment after all revenues, operating expenses, taxes, and non-operating items are accounted for. It is the primary measure of the segment's overall financial health and contribution to the company's total earnings.
Ask your AI about Zevra Therapeutics, Inc.'s business segments — net income (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude